Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CD274 | Q9NZQ7 | 3/20 | 0.46 |
| ▸ | PDCD1 | Q15116 | 2/20 | 0.46 |
| ▸ | PNMT | P11086 | 13/20 | 0.42 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.40 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.40 |
| ▸ | DRD2 | P14416 | 2/20 | 0.39 |
| ▸ | S1PR5 | Q9H228 | 1/20 | 0.39 |
| ▸ | HTR1A | P08908 | 1/20 | 0.39 |
| ▸ | HTR7 | P34969 | 1/20 | 0.39 |
| ▸ | HRH1 | P35367 | 1/20 | 0.39 |
| ▸ | DRD3 | P35462 | 1/20 | 0.39 |
| ▸ | HTR2B | P41595 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26233468 | 0.78 | CD274 (0.38) | CD274PDCD1PNMT | |
| SCHEMBL26233467 | 0.78 | CD274 (0.38) | CD274PDCD1PNMT | |
| SCHEMBL20573444 | 0.74 | S1PR5 (0.52) | TMEM97SIGMAR1DRD2S1PR5DRD3 | |
| SCHEMBL20573388 | 0.72 | S1PR5 (0.58) | TMEM97SIGMAR1DRD2S1PR5DRD3 | |
| SCHEMBL26232663 | 0.72 | CD274 (0.34) | CD274PDCD1DRD2 | |
| SCHEMBL7959566 | 0.71 | PPARG (0.54) | SIGMAR1DRD2HTR1A | |
| SCHEMBL26233474 | 0.71 | HRH1 (0.40) | CD274PDCD1HRH1 | |
| SCHEMBL26233471 | 0.71 | HRH1 (0.40) | CD274PDCD1HRH1 | |
| SCHEMBL7959540 | 0.69 | PPARG (0.53) | SIGMAR1DRD2HTR1A | |
| SCHEMBL7276869 | 0.68 | HDAC3 (0.60) | DRD2HTR1AHTR7HRH1DRD3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11760764-B2 | Methods and compositions for targeting PD-L1 | ALIGOS THERAPEUTICS, INC. (US) | 2023-09-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11760764-B2 | Methods and compositions for targeting PD-L1 | CD274, PDCD1LG2, PDCD1 | CD274 1/4885PDCD1 3/4885PNMT 4836/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.